Table of Contents Author Guidelines Submit a Manuscript
Advances in Virology
Volume 2011, Article ID 910930, 8 pages
http://dx.doi.org/10.1155/2011/910930
Review Article

Perspective: Emerging Challenges in the Treatment of Influenza and Parainfluenza in Transplant Patients

1NexBio Inc., 10665 Sorrento Valley Road, San Diego, CA 92121, USA
2Stony Brook University School of Medicine, Stony Brook, New York, NY 11794, USA

Received 19 February 2011; Revised 11 May 2011; Accepted 1 June 2011

Academic Editor: Trudy Morrison

Copyright © 2011 Ronald B. Moss et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. W. C. Leung, A. L. S. Tai, P. K. C. Cheng, M. S. Y. Kong, and W. Lim, “Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong,” Journal of Clinical Virology, vol. 46, no. 3, pp. 298–299, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. “Oseltamivir resistant 2009 pandemic influenza A(H1N1) virus infection in two summer campers receiving prophylaxis- North Carolina, 2009,” Morbidity and Mortality Weekly Report, vol. 58, no. 35, pp. 969–972, 2009.
  3. T. Suzuki, A. Portner, R. A. Scroggs et al., “Receptor specificities of human respiroviruses,” Journal of Virology, vol. 75, no. 10, pp. 4604–4613, 2001. View at Publisher · View at Google Scholar · View at PubMed
  4. A. Moscona and R. W. Peluso, “Fusion properties of cells persistently infected with human parainfluenza virus type 3: participation of hemagglutinin-neuraminidase in membrane fusion,” Journal of Virology, vol. 65, no. 6, pp. 2773–2777, 1991. View at Google Scholar · View at Scopus
  5. T. Ito, “Interspecies transmission and receptor recognition of influenza A viruses,” Microbiology and Immunology, vol. 44, no. 6, pp. 423–430, 2000. View at Google Scholar · View at Scopus
  6. M. Boeckh, “The challenge of respiratory virus infections in hematopoietic cell transplant recipients,” British Journal of Haematology, vol. 143, no. 4, pp. 455–467, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. K. M. Kunisaki and E. N. Janoff, “Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses,” The Lancet Infectious Diseases, vol. 9, no. 8, pp. 493–504, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. N. C. Issa, F. M. Marty, L. S. Gagne et al., “Seroprotective titers against 2009 H1N1 influenza a virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients,” Biology of Blood and Marrow Transplantation, vol. 17, no. 3, pp. 434–438, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. G. Ison and F. G. Hayden, “Viral infections in immunocompromised patients: what's new with respiratory viruses?” Current Opinion in Infectious Diseases, vol. 15, no. 4, pp. 355–367, 2002. View at Google Scholar · View at Scopus
  10. W. G. Nichols, K. A. Guthrie, L. Corey, and M. Boeckh, “Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy,” Clinical Infectious Diseases, vol. 39, no. 9, pp. 1300–1306, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. D. Kumar and A. Humar, “Respiratory viral infections in transplant and oncology patients,” Infectious Disease Clinics of North America, vol. 24, no. 2, pp. 395–412, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. R. Martino, R. P. Porras, N. Rabella et al., “Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses is adult recipients of hematopoietic stem cell transplants for hematologic malignancies,” Biology of Blood and Marrow Transplantation, vol. 11, no. 10, pp. 781–796, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. G. Boivin, N. Goyette, and H. Bernatchez, “Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an immunocompromised patient,” Clinical Infectious Diseases, vol. 34, no. 5, pp. E23–E25, 2002. View at Google Scholar
  14. A. I. Klimov, E. Rocha, F. G. Hayden, P. A. Shult, L. F. Roumillat, and N. J. Cox, “Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis,” Journal of Infectious Diseases, vol. 172, no. 5, pp. 1352–1355, 1995. View at Google Scholar
  15. J. Gooskens, M. Jonges, E. C. J. Claas, A. Meijer, and A. C. M. Kroes, “Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses,” Journal of Infectious Diseases, vol. 199, no. 10, pp. 1435–1441, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. Boivin, N. Goyette, and H. Bernatchez, “Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an immunocompromised patient,” Clinical Infectious Diseases, vol. 34, no. 5, pp. E23–E25, 2002. View at Google Scholar · View at Scopus
  17. J. Gooskens, M. Jonges, E. C. J. Claas, A. Meijer, P. J. van den Broek, and A. C. M. Kroes, “Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus,” Journal of the American Medical Association, vol. 301, no. 10, pp. 1042–1046, 2009. View at Publisher · View at Google Scholar · View at PubMed
  18. V. Shinde, C. B. Bridges, T. M. Uyeki et al., “Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009,” The New England Journal of Medicine, vol. 360, no. 25, pp. 2616–2625, 2009. View at Publisher · View at Google Scholar · View at PubMed
  19. F. S. Dawood, S. Jain, L. Finelli et al., “Emergence of a novel swine-origin influenza A (H1N1) virus in humans,” The New England Journal of Medicine, vol. 360, no. 25, pp. 2605–2615, 2009. View at Publisher · View at Google Scholar · View at PubMed
  20. T. Rungrotmongkol, P. Intharathep, M. Malaisree et al., “Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus,” Biochemical and Biophysical Research Communications, vol. 385, no. 3, pp. 390–394, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. http://www.who.int/csr/disease/swineflu/oseltamivirresistant20100820.pdf.
  22. I. G. Barr, L. Cui, N. Komadina et al., “A new pandemic influenza A(H1N1) genetic variant predominated in the winter 2010 influenza season in Australia, New Zealand and Singapore,” Eurosurveillance, vol. 15, no. 42, pp. 1–6, 2010. View at Google Scholar · View at Scopus
  23. R. B. Moss, R. T. Davey, R. T. Steigbigel, and F. Fang, “Targeting pandemic influenza: a primer on influenza antivirals and drug resistance,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 6, pp. 1086–1093, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. D. Kumar, M. G. Michaels, M. I. Morris et al., “Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study,” The Lancet Infectious Diseases, vol. 10, no. 8, pp. 521–526, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Espinosa-Aguilar, J. S. Green, G. N. Forrest et al., “Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiences,” Biology of Blood and Marrow Transplantation, vol. 17, no. 4, pp. 566–573, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. B. George, P. Ferguson, I. Kerridge, N. Gilroy, D. Gottlieb, and M. Hertzberg, “The clinical impact of infection with swine flu (H1N109) strain of influenza virus in hematopoietic stem cell transplant recipients,” Biology of Blood and Marrow Transplantation, vol. 17, no. 1, pp. 147–153, 2011. View at Google Scholar
  27. A. Antón, A. A. López-Iglesias, T. Tórtola et al., “Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors,” Diagnostic Microbiology and Infectious Disease, vol. 68, no. 3, pp. 214–219, 2010. View at Publisher · View at Google Scholar · View at PubMed
  28. “Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients—Seattle, Washington, 2009,” Morbidity and Mortality Weekly Report, vol. 58, pp. 893–896, 2009.
  29. M. J. Memoli, R. J. Hrabal, A. Hassantoufighi, M. C. Eichelberger, and J. K. Taubenberger, “Rapid selection of oseltamivirand peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts,” Clinical Infectious Diseases, vol. 50, no. 9, pp. 1252–1255, 2010. View at Publisher · View at Google Scholar · View at PubMed
  30. E. van der Vries, F. F. Stelma, and C. A. B. Boucher, “Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus,” The New England Journal of Medicine, vol. 363, no. 14, pp. 1381–1382, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. C. Renaud, S. A. Pergam, C. Polyak et al., “Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir,” Transplant Infectious Disease, vol. 12, no. 6, pp. 513–517, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. G. Redelman-Sidi, K. A. Sepkowitz, C. K. Huang et al., “2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients.,” The Journal of Infection, vol. 60, no. 4, pp. 257–263, 2010. View at Google Scholar · View at Scopus
  33. C. Moore, M. Galiano, A. Lackenby et al., “Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza a(H1N1) 2009 virus in a hematology unit,” Journal of Infectious Diseases, vol. 203, no. 1, pp. 18–24, 2011. View at Publisher · View at Google Scholar · View at PubMed
  34. I. M. Kidd, J. Down, E. Nastouli et al., “H1N1 pneumonitis treated with intravenous zanamivir,” The Lancet, vol. 374, no. 9694, p. 1036, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Khanna, I. Steffen, J. D. Studt et al., “Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation,” Transplant Infectious Disease, vol. 11, no. 2, pp. 100–105, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. Relenza:Highlights of prescribing information, http://www.cdc.gov/h1n1flu/eua/pdf/relenza_packageinsert.pdf.
  37. http://www.cdc.gov/H1N1flu/recommendations.htm.
  38. A. Moscona, “Global transmission of oseltamivir-resistant influenza,” The New England Journal of Medicine, vol. 360, no. 10, pp. 953–956, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. http://www.cdc.gov/h1n1flu/immunosuppression/index.htm.
  40. T. G. Sheu, A. M. Fry, R. J. Garten et al., “Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008–2010,” Journal of Infectious Diseases, vol. 203, no. 1, pp. 13–17, 2011. View at Publisher · View at Google Scholar · View at PubMed
  41. K. M. Chan-Tack, J. S. Murray, and D. B. Birnkrant, “Use of ribavirin to treat influenza,” The New England Journal of Medicine, vol. 361, no. 17, pp. 1713–1714, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. A. H. Gaur, B. Bagga, S. Barman et al., “Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza,” The New England Journal of Medicine, vol. 362, no. 1, pp. 88–89, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. X. Duval, S. van der Werf, T. Blanchon et al., “Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial,” PLoS Medicine, vol. 7, no. 11, Article ID e1000362, 2010. View at Publisher · View at Google Scholar · View at PubMed
  44. D. F. Smee, B. L. Hurst, H. Egawa, K. Takahashi, T. Kadota, and Y. Furuta, “Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells,” Journal of Antimicrobial Chemotherapy, vol. 64, no. 4, pp. 741–746, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. Y. Furuta, K. Takahashi, K. Shiraki et al., “T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections,” Antiviral Research, vol. 82, no. 3, pp. 95–102, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. Y. Itoh, K. Shinya, M. Kiso et al., “In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses,” Nature, vol. 460, no. 7258, pp. 1021–1025, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. K. Sleeman, V. P. Mishin, V. M. Deyde, Y. Furuta, A. I. Klimov, and L. V. Gubareva, “In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 6, pp. 2517–2524, 2010. View at Publisher · View at Google Scholar · View at PubMed
  48. M. Kiso, K. Takahashi, Y. Sakai-Tagawa et al., “T-705 (favipiravir) activity against lethal H5N1 influenza A viruses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 2, pp. 882–887, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. M. P. Malakhov, L. M. Aschenbrenner, D. F. Smee et al., “Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 4, pp. 1470–1479, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. J. A. Belser, X. Lu, K. J. Szretter et al., “DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza h5N1 virus infection,” Journal of Infectious Diseases, vol. 196, no. 10, pp. 1493–1499, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. G. B. Triana-Baltzer, L. V. Gubareva, A. I. Klimov et al., “Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein,” PLoS One, vol. 4, no. 11, Article ID e7838, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. G. B. Triana-Baltzer, L. V. Gubareva, J. M. Nicholls et al., “Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein,” PLoS One, vol. 4, no. 11, Article ID e7788, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. W. G. Nichols, A. J. Peck Campbell, and M. Boeckh, “Respiratory viruses other than influenza virus: impact and therapeutic advances,” Clinical Microbiology Reviews, vol. 21, no. 2, pp. 274–290, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. K. J. Henrickson, “Parainfluenza viruses,” Clinical Microbiology Reviews, vol. 16, no. 2, pp. 242–264, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. F. W. Denny and W. A. Clyde Jr., “Acute lower respiratory tract infections in nonhospitalized children,” Journal of Pediatrics, vol. 108, no. 5, pp. 635–646, 1986. View at Google Scholar · View at Scopus
  56. W. P. Glezen, A. L. Frank, L. H. Taber, and J. A. Kasel, “Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children,” Journal of Infectious Diseases, vol. 150, no. 6, pp. 851–857, 1984. View at Google Scholar · View at Scopus
  57. D. K. Shay, R. C. Holman, R. D. Newman, L. L. Liu, J. W. Stout, and L. J. Anderson, “Bronchiolitis-associated hospitalizations among US children, 1980–1996,” Journal of the American Medical Association, vol. 282, no. 15, pp. 1440–1446, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. A. J. Peck, J. A. Englund, J. Kuypers et al., “Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection,” Blood, vol. 110, no. 5, pp. 1681–1688, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. M. Boeckh, “The challenge of respiratory virus infections in hematopoietic cell transplant recipients,” British Journal of Haematology, vol. 143, no. 4, pp. 455–467, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. D. Kumar and A. Humar, “Respiratory viral infections in transplant and oncology patients,” Infectious Disease Clinics of North America, vol. 24, no. 2, pp. 395–412, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. R. A. Vilchez, J. Dauber, K. McCurry, A. Iacono, and S. Kusne, “Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function,” American Journal of Transplantation, vol. 3, no. 2, pp. 116–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. R. A. Vilchez, K. McCurry, J. Dauber et al., “The epidemiology of parainfluenza virus infection in lung transplant recipients,” Clinical Infectious Diseases, vol. 33, no. 12, pp. 2004–2008, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. J. L. Billings, M. I. Hertz, K. Savik, and C. H. Wendt, “Respiratory viruses and chronic rejection in lung transplant recipients,” Journal of Heart and Lung Transplantation, vol. 21, no. 5, pp. 559–566, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. K. J. Henrickson, “Parainfluenza viruses,” Clinical Microbiology Reviews, vol. 16, no. 2, pp. 242–264, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. R. T. Maziarz, P. Sridharan, S. Slater et al., “Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipients,” Biology of Blood and Marrow Transplantation, vol. 16, no. 2, pp. 192–198, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. S. Chakrabarti, K. E. Collingham, K. Holder, C. D. Fegan, H. Osman, and D. W. Milligan, “Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study,” Bone Marrow Transplantation, vol. 28, no. 8, pp. 759–763, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. S. Chakrabarti, I. Avivi, S. Mackinnon et al., “Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality,” British Journal of Haematology, vol. 119, no. 4, pp. 1125–1132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. W. G. Nichols, T. Gooley, and M. Boeckh, “Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience,” Biology of Blood and Marrow Transplantation, vol. 7, no. 12, supplement 1, pp. 11S–15S, 2001. View at Google Scholar
  69. V. Liu, G. S. Dhillon, and D. Weill, “A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients,” Transplant Infectious Disease, vol. 12, no. 1, pp. 38–44, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. M. Amonsen, D. F. Smith, R. D. Cummings, and G. M. Air, “Human parainfluenza viruses hPIV1 and hPIV3 bind oligosaccharides with α2-3-linked sialic acids that are distinct from those bound by H5 avian influenza virus hemagglutinin,” Journal of Virology, vol. 81, no. 15, pp. 8341–8345, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. A. Moscona, M. Porotto, S. Palmer et al., “A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo,” Journal of Infectious Diseases, vol. 202, no. 2, pp. 234–241, 2010. View at Publisher · View at Google Scholar · View at PubMed
  72. Y. B. Chen, J. Driscoll, S. L. McAfee et al., “Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation,” in Poster Presented at Annual Meeting of American Society for Blood and Bone Marrow Transplantation, February 2011.
  73. R. A. Karron, R. B. Belshe, P. F. Wright et al., “A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants,” Pediatric Infectious Disease Journal, vol. 22, no. 5, pp. 394–405, 2003. View at Publisher · View at Google Scholar
  74. M. Sato and P. F. Wright, “Current status of vaccines for parainfluenza virus infections,” The Pediatric Infectious Disease Journal, vol. 27, no. 10, pp. S123–125, 2008. View at Google Scholar · View at Scopus